Jurgen Klaus Beck
Director/Board Member at Paion Holdings UK Ltd.
Jurgen Klaus Beck active positions
Companies | Position | Start | End |
---|---|---|---|
Paion Holdings UK Ltd.
Paion Holdings UK Ltd. Financial ConglomeratesFinance Part of PAION AG, Paion Holdings UK Ltd. functions as an investment holding company. The company is based in Edinburgh, UK. The British company was founded in 1996. Abdelghani Omari has been the CEO of the company since 2012. | Director/Board Member | 2018-01-24 | - |
Paion UK Ltd.
Paion UK Ltd. Pharmaceuticals: MajorHealth Technology Part of PAION AG, Paion UK Ltd. is a specialty pharmaceutical company that develops and commercializes innovative drugs for out-patient and hospital-based sedation and critical care services. Paion was founded in 1995 and is based in Cambridge, UK, with another site in Germany. Paion's vision is to become an acknowledged "PAIONeer" in sedation and critical care services. The British company's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate. The company is mainly focusing on completing the development program for procedural sedation and planning to continue the clinical development program for remimazolam in the indication general in the EU. | Director/Board Member | 2018-01-24 | - |
Career history of Jurgen Klaus Beck
Statistics
International
United Kingdom | 3 |
Operational
Director/Board Member | 2 |
Sectoral
Finance | 2 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Paion Holdings UK Ltd.
Paion Holdings UK Ltd. Financial ConglomeratesFinance Part of PAION AG, Paion Holdings UK Ltd. functions as an investment holding company. The company is based in Edinburgh, UK. The British company was founded in 1996. Abdelghani Omari has been the CEO of the company since 2012. | Finance |
Paion UK Ltd.
Paion UK Ltd. Pharmaceuticals: MajorHealth Technology Part of PAION AG, Paion UK Ltd. is a specialty pharmaceutical company that develops and commercializes innovative drugs for out-patient and hospital-based sedation and critical care services. Paion was founded in 1995 and is based in Cambridge, UK, with another site in Germany. Paion's vision is to become an acknowledged "PAIONeer" in sedation and critical care services. The British company's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate. The company is mainly focusing on completing the development program for procedural sedation and planning to continue the clinical development program for remimazolam in the indication general in the EU. | Health Technology |
- Stock Market
- Insiders
- Jurgen Klaus Beck
- Experience